162. Pemphigoid Clinical trials / Disease details
Clinical trials : 90 / Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04128176 (ClinicalTrials.gov) | May 25, 2023 | 12/10/2019 | Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid | Bullous Pemphigoid | Drug: Rituximab combined with Omalizumab | University of California, Davis | NULL | Not yet recruiting | 18 Years | 90 Years | All | 15 | Phase 3 | United States |
2 | NCT00472030 (ClinicalTrials.gov) | August 2007 | 8/5/2007 | Efficacy and Safety of Omalizumab in Bullous Pemphigoid | An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid | Bullous Pemphigoid | Drug: Omalizumab;Drug: prednisone | University of Iowa | Genentech, Inc. | Completed | 18 Years | N/A | All | 2 | Phase 4 | United States |